← Leaderboards
Kimberly Stegmaier
Dana-Farber Cancer Institute
$26,925,503
Attributed
$32,193,154
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $18.5M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,396,831 · 16
By mechanism
U54$16,879,310 · 4
R01$10,662,496 · 4
R35$10,462,821 · 2
OT2$3,108,431 · 1
U01$2,317,710 · 1
P50$792,818 · 1
Top collaborators
- Eric Alejandro Sweet-Cordero9 shared
- William A Weiss5 shared
- Scott A Armstrong3 shared
- Robbie G. Majzner3 shared
- Miguel Nicolas Rivera3 shared
- Andrew L Kung2 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Thomas L Benjamin$17,343,201
- William C Hahn$46,384,528
- Karl Hsu$475,430
- Andrew L Kung$5,571,759
- Scott Loren Pomeroy$18,531,010
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCellsEwings SarcomaMalignant Childhood NeoplasmBiologyMolecularEpigenetic ProcessPathogenesisGeneticGenomicsChildLeadChromatinGenesClinical TrialsGenetic TranscriptionMemberTranscription FactorTumorOncogenicDependenceResponseFunctional GenomicsComplex
Grant awards (57)
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)$1,752,813
OT2 · FY2025 · CA · contact PI
Targeting Pediatric Cancer Vulnerabilities$1,065,492
R35 · FY2025 · CA · contact PI
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma$767,167
U01 · FY2025 · CA
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma$713,593
R01 · FY2025 · CA · contact PI
Targeting neuroblastoma cell state plasticity$407,872
P01 · FY2025 · CA · contact PI
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)$1,355,618
OT2 · FY2024 · CA · contact PI
Targeting Pediatric Cancer Vulnerabilities$1,012,869
R35 · FY2024 · CA · contact PI
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma$755,393
U01 · FY2024 · CA
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma$677,914
R01 · FY2024 · CA · contact PI
Targeting Pediatric Cancer Vulnerabilities$1,066,178
R35 · FY2023 · CA · contact PI
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma$795,150
U01 · FY2023 · CA
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma$733,093
R01 · FY2023 · CA · contact PI
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer$1,025,512
R35 · FY2022 · CA · contact PI
Administrative Core$505,427
U54 · FY2022 · CA · contact PI
The Center for Therapeutic Targeting of EWS-oncoproteins$505,427
U54 · FY2022 · CA · contact PI
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer$1,046,441
R35 · FY2021 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$396,547
R01 · FY2021 · CA · contact PI
The Center for Therapeutic Targeting of EWS-oncoproteins$198,250
U54 · FY2021 · CA · contact PI
Targeting SYK Kinase in AML$20,549
P50 · FY2021 · CA · contact PI
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer$1,091,957
R35 · FY2020 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$479,795
R01 · FY2020 · CA · contact PI
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer$1,015,049
R35 · FY2019 · CA · contact PI
Targeting BET-bromodomains in neuroblastoma$641,224
R01 · FY2019 · NS
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$384,651
R01 · FY2019 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$119,844
R01 · FY2019 · CA · contact PI
The Center for Therapeutic Targeting of EWS-oncoproteins$12,500,000
U54 · FY2018 · CA · contact PI
Project 3: Delineating and Drugging the Core Transcriptional Circuitry in Ewing Sarcoma$2,499,136
U54 · FY2018 · CA · contact PI
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer$1,046,441
R35 · FY2018 · CA · contact PI
Administrative Core$671,070
U54 · FY2018 · CA · contact PI
Targeting BET-bromodomains in neuroblastoma$651,177
R01 · FY2018 · NS
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$396,547
R01 · FY2018 · CA · contact PI
Targeting SYK Kinase in AML$348,122
P50 · FY2018 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$228,600
R01 · FY2018 · CA · contact PI
Targeting SYK Kinase in AML$90,131
P50 · FY2018 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$40,302
R01 · FY2018 · CA · contact PI
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer$1,046,441
R35 · FY2017 · CA · contact PI
Targeting BET-bromodomains in neuroblastoma$675,172
R01 · FY2017 · NS
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$396,547
R01 · FY2017 · CA · contact PI
Targeting SYK Kinase in AML$334,016
P50 · FY2017 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$228,600
R01 · FY2017 · CA · contact PI
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer$1,046,441
R35 · FY2016 · CA · contact PI
Targeting BET-bromodomains in neuroblastoma$669,055
R01 · FY2016 · NS
Targeting BET-bromodomains in neuroblastoma$698,744
R01 · FY2015 · NS
Validating Syk as a Target for AML Therapy$387,731
R01 · FY2015 · CA · contact PI
Validating Syk as a Target for AML Therapy$387,775
R01 · FY2014 · CA · contact PI
Validating Syk as a Target for AML Therapy$331,098
R01 · FY2013 · CA · contact PI
Targeting the ETS Transcription Factor Rearrangement EWS/FLI in Ewing's Sarcoma$42,438
R03 · FY2013 · DA
Validating Syk as a Target for AML Therapy$352,231
R01 · FY2012 · CA · contact PI
Targeting the ETS Transcription Factor Rearrangement EWS/FLI in Ewing's Sarcoma$43,750
R03 · FY2012 · DA
Validating Syk as a Target for AML Therapy$352,231
R01 · FY2011 · CA · contact PI
Validating Syk as a Target for AML Therapy$362,088
R01 · FY2010 · CA · contact PI
Validating Syk as a Target for AML Therapy$357,937
R01 · FY2009 · CA · contact PI
Chemical Genomics Approach to Leukemia Differentiation$135,837
K08 · FY2007 · CA · contact PI
Chemical Genomics Approach to Leukemia Differentiation$135,837
K08 · FY2006 · CA · contact PI
Chemical Genomics Approach to Leukemia Differentiation$135,837
K08 · FY2005 · CA
Chemical Genomics Approach to Leukemia Differentiation$135,837
K08 · FY2004 · CA
Chemical Genomics Approach to Leukemia Differentiation$135,837
K08 · FY2003 · CA